Comparative Pharmacology
Head-to-head clinical analysis: FOSCAVIR versus LIVTENCITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSCAVIR versus LIVTENCITY.
FOSCAVIR vs LIVTENCITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Foscarnet is a pyrophosphate analog that selectively inhibits viral DNA polymerase and reverse transcriptase by binding to the pyrophosphate binding site, preventing the cleavage of pyrophosphate from deoxynucleotide triphosphates, thereby inhibiting viral DNA synthesis. It does not require activation by viral thymidine kinase, making it active against acyclovir-resistant HSV and VZV, and ganciclovir-resistant CMV.
LIVTENCITY (maribavir) is an inhibitor of the human cytomegalovirus (CMV) UL97 protein kinase, which is essential for viral DNA replication, encapsidation, and egress of mature virions from the infected cell. By blocking UL97 kinase activity, maribavir inhibits viral replication.
Induction: 60 mg/kg IV every 8 hours for 2-3 weeks, then maintenance: 90-120 mg/kg IV once daily. Administer as a 2-hour infusion via central line.
200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in patients with normal renal function; can extend to 48-120 hours in severe renal impairment (CrCl <20 mL/min), requiring dose adjustment and therapeutic drug monitoring.
Terminal elimination half-life is approximately 20 hours, supporting once-daily dosing for sustained antiviral activity.
Primarily renal excretion (>80% as unchanged drug) via glomerular filtration and tubular secretion; minimal biliary/fecal elimination (<5%).
Primarily hepatobiliary excretion; unchanged drug and metabolites eliminated in feces (86%) and urine (14%).
Category C
Category C
Antiviral
Antiviral